This study is in progress, not accepting new patients
An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Andrew Ko
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Bristol-Myers Squibb
- ID
- NCT02743494
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated